Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu
syndrome, is an autosomal dominant disorder that causes abnormal blood vessel formation …

Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the
emergence and development of antiangiogenic therapies to eliminate bleeding …

Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of …

Objective To present a multiyear clinical experience with intravenous bevacizumab for the
management of severe gastrointestinal bleeding and/or epistaxis in patients with hereditary …

Background Bevacizumab—a humanized monoclonal antibody—has been widely used to
treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has …

Importance Epistaxis is a major factor negatively affecting quality of life in patients with
hereditary hemorrhagic telangiectasia (HHT; also known as Osler-Weber-Rendu disease) …

Hereditary haemorrhagic telangiectasia (HHT) is a rare vascular multisystemic disease that
leads to epistaxis, anaemia due to blood loss, and arteriovenous malformations (AVMs) in …

Background Hereditary haemorrhagic telangiectasia (HHT) is a rare hereditary multisystem
vascular disorder causing visceral arteriovenous malformations and mucocutaneous …

Background Bevacizumab, an anti-VEGF monoclonal antibody, has recently emerged as a
new option for severe forms of hereditary hemorrhagic telangiectasia (HHT). Its utilization in …

Etiology and Genetics of Congenital Vascular Lesions - Otolaryngologic Clinics of North
America Skip to Main Content Skip to Main Menu Otolaryngologic Clinics Log in Register Log in …